AH Related Analyst Ratings
-
Dougherty & Co Downgrades Accretive Health (AH) to Neutral
-
Raymond James Starts Accretive Health (AH) at Strong Buy
-
Dougherty & Co Starts Accretive Health (AH) at Buy
-
UBS Raises PT on Accretive Health (AH); Highlights From Management Meeting
-
UBS Raises Price Target on Accretive Health (AH); Wheeling and Dealing Removes Substantial Overhang
-
Oppenheimer Reiterates an 'Outperform' on Accretive Health (AH); Settling Up with Minnesota AG
-
Oppenheimer Reiterates an 'Outperform' on Accretive Health (AH); Believe in Ascension Deal
-
UPDATE - UBS Downgraded Accretive Health (AH) to Neutral; Possibility Of More Issues Lurking
-
UBS Downgrades Accretive Health (AH) to Neutral
-
Credit Suisse Says Downside in Accretive Health (AH) Shares 'Overdone'
-
Accretive (AH) Shares Slammed as Piper Sees Headwinds in Debt-Collection Suit
-
Goldman Sachs Downgrades Accretive Health (AH) to Neutral On Contract Loss
-
Baird Downgrades Accretive Health (AH) to Neutral
-
Goldman Sachs Comments on Top HCIT Picks: Cerner (CERN), Accretive Health (AH) and Computer Programs and Systems (CPSI)
-
Oppenheimer Upgrades Accretive Health (AH) to Outperform; Looking Past 4Q Concerns
-
Cowen Starts Accretive Health (AH) at Neutral
-
Piper Jaffray Starts Accretive Health (AH) at Underweight
-
Goldman Sachs Upgrades Accretive Health (AH) to Buy
-
UPDATE - UBS Initiates Coverage on Accretive Health (AH) with a Buy; The Right Offerings at the Right Time
-
UBS Starts Accretive Health (AH) at Buy
-
Goldman Sachs Resumes Accretive Health (AH) at Neutral
-
Baird Upgrades Accretive Health (AH) to Outperform
-
Oppenheimer Starts MDRX, MDAS, CPSI at Outperform, QSII, AH, EM at Perform, ATHN, CERN at Underperform
-
Credit Suisse Starts Accretive Health (AH) at Outperform
-
Baird Downgrades Accretive Health (AH) to Neutral
-
Morgan Keegan Starts Accretive Health (AH) at Market Perform
-
Credit Suisse Reinstates Coverage on Accretive Health (AH) at Outperform
-
Brean Murray Carret & Co. Upgrades Accretive Health (AH) to Buy; Business Model Outweighs Near-term Delays
-
Baird Upgrades Accretive Health (AH) to Outperform
-
Brean Murray Initiates Coverage on Accretive Health (AH) with a Hold; All Things RCM
-
William Blair Initiates Coverage on Accretive Health (AH) with a Market Perform
-
Goldman Sachs Starts Accretive Health (AH) at Neutral
-
Credit Suisse Initiates Coverage on Accretive Health (AH) with an Outperform
-
Morgan Stanley Initiates Coverage on Accretive Health (AH) with a Equalweight
-
J.P. Morgan & Baird Initiate Coverage on Accretive Health (AH)
-
JP Morgan downgrades Armor Holdings (AH) to Neutral
-
Cramer Highlights CRDN and ATK Related to Armor Holdings (AH) Buyout
-
Lehman Brothers upgrades Armor Holdings (AH) to Overweight
-
Armor Holdings Inc. (AH) Removed from Goldman Sachs Conviction Buy List
-
Wachovia Resumes Coverage on Armor Holdings (AH) at Outperform
-
Prudential upgrades Armor Holdings (AH) to Overweight
-
Armor Holdings (AH) Upgraded by Goldman Sachs; Company Acquires Integrated Textile Systems
-
Bear Stearns upgrades AH to Outperform
-
J.P. Morgan Comments On AH/SVC Acquisition
-
Wachovia Securities Upgrades AH
-
Citigroup Starts CRDN at Hold
-
J.P. Morgan Upgrades Armor Holdings
-
Prudential Starts Aerospace and Defense Electronics Sector at Neutral
-
Goldman Sachs upgrades AH to In-Line
-
CSFB Initiates Coverage on US Aerospace Defense sector
Back to AH Stock Lookup
